Cargando…

A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents

BACKGROUND: Currently, effective detection and treatment of cutaneous malignant melanoma (CMM) still face severe challenges. Ultrasound molecular imaging as a noninvasive and easy-to-operate method is expected to bring improvements for tumor detection. PURPOSE: The aim of this research is to prepare...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hengli, Cai, Wenbin, Lv, Wei, Zhao, Ping, Shen, Yamei, Zhang, Longfang, Ma, Bin, Yuan, Lijun, Duan, Yunyou, Yao, Kechun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731466/
https://www.ncbi.nlm.nih.gov/pubmed/31564866
http://dx.doi.org/10.2147/IJN.S207419
_version_ 1783449679904636928
author Yang, Hengli
Cai, Wenbin
Lv, Wei
Zhao, Ping
Shen, Yamei
Zhang, Longfang
Ma, Bin
Yuan, Lijun
Duan, Yunyou
Yao, Kechun
author_facet Yang, Hengli
Cai, Wenbin
Lv, Wei
Zhao, Ping
Shen, Yamei
Zhang, Longfang
Ma, Bin
Yuan, Lijun
Duan, Yunyou
Yao, Kechun
author_sort Yang, Hengli
collection PubMed
description BACKGROUND: Currently, effective detection and treatment of cutaneous malignant melanoma (CMM) still face severe challenges. Ultrasound molecular imaging as a noninvasive and easy-to-operate method is expected to bring improvements for tumor detection. PURPOSE: The aim of this research is to prepare novel phase-change ultrasound contrast agents, Nds-IR780, which can perform not only dual-mode molecule-targeted imaging but also targeted photothermal therapy for CMM. METHODS: A double emulsion process was used to prepare the Nds-IR780. Then, the entrapment rate and drug loading of IR-780 iodide in Nds-IR780 were detected by high-performance liquid chromatography. The biocompatibility of Nds-IR780 was evaluated by a CCK-8 assay and the characteristics and stability of that were verified through the particle size analyzer, laser scanning confocal microscopy (LSCM) and transmission electron microscopy (TEM). The abilities of dual-mode molecule-targeted imaging and targeted photothermal therapy for Nds-IR780 were confirmed via the in vitro and in vivo experiments. RESULTS: Nds-IR780 had good size distribution, polydispersity index, stability and biosafety. The in vitro and in vivo experiments confirmed that Nds-IR780 were capable of targeting CMM cells with high affinity (22.4±3.2%) and facilitating dual-mode imaging to detect the primary lesion and sentinel lymph nodes (SLNs) of CMM. Furthermore, the photothermal ablation of CMM mediated by Nds-IR780 was very effective in vivo. CONCLUSION: The newly prepared Nds-IR780 were observed to be effective targeted theranostic probe for the precise detection and targeted treatment of CMM.
format Online
Article
Text
id pubmed-6731466
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67314662019-09-27 A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents Yang, Hengli Cai, Wenbin Lv, Wei Zhao, Ping Shen, Yamei Zhang, Longfang Ma, Bin Yuan, Lijun Duan, Yunyou Yao, Kechun Int J Nanomedicine Original Research BACKGROUND: Currently, effective detection and treatment of cutaneous malignant melanoma (CMM) still face severe challenges. Ultrasound molecular imaging as a noninvasive and easy-to-operate method is expected to bring improvements for tumor detection. PURPOSE: The aim of this research is to prepare novel phase-change ultrasound contrast agents, Nds-IR780, which can perform not only dual-mode molecule-targeted imaging but also targeted photothermal therapy for CMM. METHODS: A double emulsion process was used to prepare the Nds-IR780. Then, the entrapment rate and drug loading of IR-780 iodide in Nds-IR780 were detected by high-performance liquid chromatography. The biocompatibility of Nds-IR780 was evaluated by a CCK-8 assay and the characteristics and stability of that were verified through the particle size analyzer, laser scanning confocal microscopy (LSCM) and transmission electron microscopy (TEM). The abilities of dual-mode molecule-targeted imaging and targeted photothermal therapy for Nds-IR780 were confirmed via the in vitro and in vivo experiments. RESULTS: Nds-IR780 had good size distribution, polydispersity index, stability and biosafety. The in vitro and in vivo experiments confirmed that Nds-IR780 were capable of targeting CMM cells with high affinity (22.4±3.2%) and facilitating dual-mode imaging to detect the primary lesion and sentinel lymph nodes (SLNs) of CMM. Furthermore, the photothermal ablation of CMM mediated by Nds-IR780 was very effective in vivo. CONCLUSION: The newly prepared Nds-IR780 were observed to be effective targeted theranostic probe for the precise detection and targeted treatment of CMM. Dove 2019-09-02 /pmc/articles/PMC6731466/ /pubmed/31564866 http://dx.doi.org/10.2147/IJN.S207419 Text en © 2019 Yang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Hengli
Cai, Wenbin
Lv, Wei
Zhao, Ping
Shen, Yamei
Zhang, Longfang
Ma, Bin
Yuan, Lijun
Duan, Yunyou
Yao, Kechun
A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title_full A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title_fullStr A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title_full_unstemmed A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title_short A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
title_sort new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731466/
https://www.ncbi.nlm.nih.gov/pubmed/31564866
http://dx.doi.org/10.2147/IJN.S207419
work_keys_str_mv AT yanghengli anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT caiwenbin anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT lvwei anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT zhaoping anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT shenyamei anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT zhanglongfang anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT mabin anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT yuanlijun anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT duanyunyou anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT yaokechun anewstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT yanghengli newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT caiwenbin newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT lvwei newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT zhaoping newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT shenyamei newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT zhanglongfang newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT mabin newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT yuanlijun newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT duanyunyou newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents
AT yaokechun newstrategyforaccuratetargeteddiagnosisandtreatmentofcutaneousmalignantmelanomadualmodephasechangelipidnanodropletsasultrasoundcontrastagents